The Cyltezo Savings Copay Program (BI Solutions Plus) has ended. Below is what we verified about it, plus the closest alternatives we track.
Boehringer Ingelheim Pharmaceuticals, Inc. discontinued the Cyltezo Savings Copay Program (BI Solutions Plus) on May 1, 2026.
Boehringer Ingelheim Cares Foundation, Inc. discontinued the BI Cares Foundation Patient Assistance Program (Cyltezo) on July 15, 2026.
Same active ingredient, different product: Abrilada (adalimumab-afzb, 1 active program), Amjevita (adalimumab-atto, 2 active programs), Hadlima (adalimumab-bwwd, 2 active programs), Humira (adalimumab, 1 active program), Hyrimoz (adalimumab-adaz, 2 active programs), Yusimry (adalimumab-aqvh, 2 active programs).
Cyltezo (adalimumab-adbm) is a tnf-alpha inhibitor (biologic, adalimumab biosimilar - interchangeable) made by Boehringer Ingelheim. It is commonly prescribed for: Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease, Ulcerative colitis, Plaque psoriasis, Hidradenitis suppurativa, Uveitis.
This is the program we tracked and the final terms we verified before it ended.
Boehringer Ingelheim Pharmaceuticals, Inc. · Cyltezo
Patient pays: eligible patients may pay as little as $0 per month
commercial insurance
Boehringer Ingelheim Cares Foundation, Inc. · Cyltezo
uninsured · underinsured
Not anymore. Boehringer Ingelheim Pharmaceuticals, Inc. ran the Cyltezo Savings Copay Program (BI Solutions Plus), but it ended on May 1, 2026 and we have not verified an active replacement. The alternatives we track are listed on this page.
Manufacturers like Boehringer Ingelheim use "patient support program" as an umbrella term for nurse lines, insurance navigation, and financial help. The financial help is what we track here. The support phone line is listed on the official program site linked above.